重组抗VEGF人源化单克隆抗体F0001的临床前主要药效学研究(4)
[5] Kim KJ， Li B， Winer J， et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo[J]. Nature， 1993， 362(6423)： 841-844.
[6] Presta LG， Chen H， O’Connor SJ， et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders[J]. Cancer Res， 1997， 57(20)： 4593-4599.
[7] Gerber HP， Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies[J]. Cancer Res， 2005， 65(3)： 671-680.
[8] Breslin JW， Pappas PJ， Cerveira JJ， et al. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide[J]. Am J Physiol Heart Circ Physiol， 2003， 284(1)： H92-H100.
[9] Wang Y， Fei D， Vanderlaan M， et al. Biological activity of bevacizumab， a humanized anti-VEGF antibody in vitro[J]. Angiogenesis， 2004， 7(4)： 335-345.
[10] Lin YS， Nguyen C， Mendoza JL， et al. Preclinical pharmacokinetics， interspecies scaling， and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor[J]. J Pharmacol Exp Ther， 1999， 288(1)： 371-378.
[11] 國家药品监督管理局药品审评中心. 生物类似药研发与评价技术指导原则(试行)[EB/OL]. [2019-02-28]. http： // www.cde.org.cn/zdyz.do？method=largePage&id=243., 百拇医药(王罗春 瞿爱东 楼丽广)
[6] Presta LG， Chen H， O’Connor SJ， et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders[J]. Cancer Res， 1997， 57(20)： 4593-4599.
[7] Gerber HP， Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies[J]. Cancer Res， 2005， 65(3)： 671-680.
[8] Breslin JW， Pappas PJ， Cerveira JJ， et al. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide[J]. Am J Physiol Heart Circ Physiol， 2003， 284(1)： H92-H100.
[9] Wang Y， Fei D， Vanderlaan M， et al. Biological activity of bevacizumab， a humanized anti-VEGF antibody in vitro[J]. Angiogenesis， 2004， 7(4)： 335-345.
[10] Lin YS， Nguyen C， Mendoza JL， et al. Preclinical pharmacokinetics， interspecies scaling， and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor[J]. J Pharmacol Exp Ther， 1999， 288(1)： 371-378.
[11] 國家药品监督管理局药品审评中心. 生物类似药研发与评价技术指导原则(试行)[EB/OL]. [2019-02-28]. http： // www.cde.org.cn/zdyz.do？method=largePage&id=243., 百拇医药(王罗春 瞿爱东 楼丽广)